Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune Disease and Transplant Rejection Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD40LG drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD40LG Recombinant Protein (ECD, Trimeric) — High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed. Trimeric active form availability. | View CD40LG Products |
| Receptor | CD40-Fc Fusion Protein — HEK293 Expressed, Native Glycosylation. For blockade assays. | View CD40 Products |
| Gene Delivery | CD40LG Lentivirus Premade Particles (Full-length ORF) for stable cell line generation. | View CD40LG Products |
| Benchmark Antibody | Anti-CD40LG (Sequence of Frexalimab / Dapirolizumab / Tegoprubart biosimilar) — Recombinant positive control. | View CD40LG Products |
| Validator | CD40LG siRNA Set — For knockdown verification. | View CD40LG Products |
| Related Target A | CD40 (TNFRSF5) — Primary receptor, essential for interaction blocking assays. | View CD40 Products |
| Related Target B | BAFF — Synergistic B-cell survival factor often targeted in combination. | View BAFF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining Trimeric Conformation | HEK293 Expressed (Native Glycosylation), designed to maintain physiological trimeric structure with >95% purity. |
| Platelet Aggregation / Fc-Receptor Binding | Custom Fc-silent mutants and native control proteins available to rigorously test off-target Fc-γRIIa interactions. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included. |
| False Positives | Validated siRNA included for specificity checks. |
Live CD40LG (CD154) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD40LG therapeutics has experienced a renaissance, driven by next-generation Fc-engineered antibodies and PEGylated Fab fragments. After first-generation molecules failed due to thromboembolic complications, major players are now advancing Fc-silent modalities. As these second-generation therapies reach late-stage clinical trials for Systemic Lupus Erythematosus (SLE) and Multiple Sclerosis, the next wave of R&D is targeting broader autoimmune indications and precision transplantation protocols.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Fc-Silent mAb | Sanofi (Frexalimab) | Multiple Sclerosis, SLE | Receptor Blocking Assay (Need high-purity trimeric ECD) |
| PEGylated Fab | Biogen / UCB (Dapirolizumab pegol) | Lupus (SLE) | Affinity Validation (Need stable, sequence-verified antigen) |
| Bispecific / Combinations | Various Biotech | Refractory Autoimmunity | Dual-Binding Assay (Need Cross-reactive CD40/CD40LG proteins) |
Target Biology & Key Mutations
CD40LG (CD154) is a 39 kDa type II transmembrane glycoprotein belonging to the tumor necrosis factor (TNF) superfamily. It contains a conserved TNF homology domain (THD) responsible for trimerization and receptor binding. Mutations in CD40LG cause X-linked Hyper-IgM syndrome type 1 (HIGM1), a primary immunodeficiency characterized by defective class switch recombination. Known missense mutations include rs104894774 (p.Leu155Pro), VAR_017925 (p.Arg216His), and VAR_017929 (p.Ser225Arg), which impair CD40 binding or protein stability. Understanding these mutations is critical for designing therapeutics that avoid off-target effects and for developing patient stratification strategies.
Therapeutic Development Challenges
The development of CD40L-targeted therapies has been historically hindered by thromboembolic risks associated with FcγRIIa-mediated platelet activation. Second-generation approaches employ Fc-silent antibodies (e.g., IgG1 LALA mutations, IgG4) or Fab fragments to eliminate Fc effector functions. Assay requirements include:
- High-affinity binding to trimeric CD40L ECD (SPR/BLI)
- Potent blockade of CD40-CD40L interaction (cell-based flow cytometry or ELISA)
- Fc-receptor binding panel to confirm absence of FcγRIIa engagement
- Platelet aggregation assays as safety gate
TarMart's reagent toolbox provides the essential components: HEK293-expressed trimeric CD40L protein (native glycosylation, >95% purity), CD40-Fc fusion, benchmark antibodies (including sequences of Frexalimab, Dapirolizumab, and Tegoprubart), lentiviral ORF particles, and siRNA validation sets. These enable robust assay development for screening, optimization, and safety assessment.